抗氧化剂对男性因素不孕的影响:MOXI随机临床试验
这项多中心双盲安慰剂对照试验纳入174对男性因素不孕夫妇,男性随机接受含维生素C、E、硒、左卡尼汀、锌、叶酸、番茄红素的抗氧化剂复方或安慰剂治疗3-6个月。结果显示抗氧化剂未改善精液参数或精子DNA完整性,6个月累积活产率两组无差异(15% vs 24%)。
要点
- 抗氧化剂复方未改善男性因素不孕患者的精液参数或精子DNA碎片率
- 抗氧化剂组与安慰剂组6个月累积活产率无显著差异
- 不推荐常规使用抗氧化剂治疗男性因素不孕以改善生育结局
核心结论
- 抗氧化剂不改善男性因素不孕男性的精液参数或DNA完整性。
- 尽管样本量有限,本研究提示男性抗氧化剂治疗不提高体内妊娠或活产率。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照试验,含内部预试验。
- 美国9个生育中心,2015年12月至2018年12月。
- 男性N=174,精子浓度≤15百万/mL、活力≤40%、正常形态≤4%或DNA碎片>25%;女性伴侣排卵正常、≤40岁、输卵管通畅。
- 抗氧化剂组n=85,安慰剂组n=86;治疗至少3个月、最多6个月。
- 前3个月自然试孕,第4-6个月女性伴侣接受枸橼酸氯米芬促排卵联合宫内授精。
主要发现
- 治疗3个月后精子浓度变化:抗氧化剂组中位数-4.0(四分位距-12.0, 5.7)百万/mL,安慰剂组+2.4(-9.0, 15.5)百万/mL。
- 两组精子形态、活力或DNA碎片变化无统计学显著差异。
- 66例少精子症男性治疗3个月精子浓度:抗氧化剂组8.5(4.8, 15.0)百万/mL vs 对照组15.0(6.0, 24.0)百万/mL。
- 75例弱精子症男性治疗3个月活力:34% ± 16.3% vs 36.4% ± 15.8%。
- 44例高DNA碎片男性治疗3个月DNA碎片:29.5%(21.6%, 36.5%)vs 28.0%(20.6%, 36.4%)。
关键数值与推荐
- 抗氧化剂复方每日含维生素C 500 mg、维生素E 400 mg、硒0.20 mg、左卡尼汀1,000 mg、锌20 mg、叶酸1,000 μg、番茄红素10 mg。
临床怎么用
- 不应常规推荐抗氧化剂复方用于改善男性因素不孕患者的精液参数或提高活产率。
- 对男性因素不孕夫妇,应基于证据选择其他干预措施,而非抗氧化剂经验性治疗。
局限性
- 样本量有限,可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether antioxidants improve male fertility, as measured by semen parameters and DNA fragmentation at 3 months and pregnancy resulting in live birth after up to 6 months of treatment, among couples with male factor infertility. DESIGN: Multicenter, double-blind, randomized, placebo-controlled trial with an internal pilot study. SETTING: Nine fertility centers in the United States from December 2015 to December 2018. PATIENT(S): Men (N = 174) with sperm concentration ≤15 million/mL, motility ≤40%, normal morphology ≤4%, or DNA fragmentation >25%, and female partners who were ovulatory, ≤40 years old, and had documented tubal patency. INTERVENTION(S): Males randomly assigned to receive an antioxidant formulation (n = 85) containing 500 mg of vitamin C, 400 mg of vitamin E, 0.20 mg of selenium, 1,000 mg of l-carnitine, 20 mg of zinc, 1,000 μg of folic acid, 10 mg of lycopene daily, or placebo (n = 86). Treatment lasted for a minimum of 3 months and maximum of 6 months, and couples attempted to conceive naturally during the first 3 months and with clomiphene citrate with intrauterine insemination of the female partner in months 4 through 6. MAIN OUTCOME MEASURE(S): Primary outcome was live birth; secondary outcomes included pregnancy within 6 months of treatment. For the internal pilot, the primary outcomes were semen parameters and sperm DNA fragmentation index after 3 months of treatment. RESULT(S): In the Males, Antioxidants, and Infertility (MOXI) study, after 3 months of treatment, the change in sperm concentration differed between the antioxidant group (median -4.0 [interquartile range-12.0, 5.7] million/mL) and placebo group (+2.4 [-9.0, 15.5] million/mL). However, there were no statistically significant differences between the two groups for changes in sperm morphology, motility, or DNA fragmentation. Among the 66 oligospermic men at randomization, sperm concentration did not differ at 3 months between the antioxidant and control groups: 8.5 (4.8, 15.0) million/mL versus 15.0 (6.0, 24.0) million/mL. Of the 75 asthenospermic men, motility did not differ at 3 months: 34% ± 16.3% versus 36.4% ± 15.8%. Among the 44 men with high DNA fragmentation, DNA fragmentation did not differ at 3 months: 29.5% (21.6%, 36.5%) versus 28.0% (20.6%, 36.4%). In the entire cohort, cumulative live birth did not differ at 6 months between the antioxidant and placebo groups: 15% versus 24%. CONCLUSION(S): Antioxidants do not improve semen parameters or DNA integrity among men with male factor infertility. Although limited by sample size, this study suggests that antioxidant treatment of the male partner does not improve in vivo pregnancy or live-birth rates. CLINICAL TRIAL REGISTRATION NUMBER: NCT02421887.
引用
- Steiner AZ, Hansen KR, Barnhart KT, et al. The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertil Steril. 2020. PMID: 32111479. doi:10.1016/j.fertnstert.2019.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。